

TECH PARK BASEL

Zielgruppe des Tech Parks Basel sind innovative Jungunternehmen aus der Life Sciences-Industrie, der chemischen Industrie, der Umwelt- und Energietechnologie, der Nanotechnologie sowie der Informations- und Kommunikationstechnologie. Die Unternehmen werden auf Basis ihres Innovationspotenzials sowie ihres Potenzials, mittelfristig Arbeitsplätze in der Region zu schaffen und Wertschöpfung zu generieren, ausgewählt.

Der kommerzielle Start dieser Jungunternehmen aus Hochtechnologiebranchen wird durch das Angebot von Büro-, Labor- und Lagerflächen sowie Infrastrukturen zur gemeinschaftlichen Nutzung vereinfacht. Zudem stellt der Tech Park Basel grundlegende Dienstleistungen zur Verfügung.

Erfolgreiche Jungunternehmen bleiben oft nur wenige Jahre im Tech Park Basel. Nach Etablierung des Unternehmens und dessen Produkten im Markt finden die Unternehmen einen neuen Standort im regionalen Immobilienmarkt.

Der Tech Park Basel ist nicht gewinnorientiert, sondern ist ein Instrument der baselstädtischen Standortförderung. Im Verbund mit weiteren Instrumenten leistet er einen Beitrag zur Erhöhung der Zahl der in der Region Basel neu gegründeten Hochtechnologie-Unternehmen.

ERWEITERUNGEN TECH PARK BASEL

Aufgrund der grossen Nachfrage und um den Expansionsplänen der bestehenden Mieter gerecht zu werden, wurde der im 2011 erstellte Tech Park Basel im Sommer 2014 zum ersten Mal erweitert. Neben einer Verdopplung der Labor- und Büroflächen wurden auch ein zentraler Empfangsbereich sowie ein Auditorium erstellt.

Die anhaltend hohe Auslastung der Labor- und Büroflächen im Tech Park Basel sowie die Verfügbarkeit von freien Flächen im gleichen Gebäude haben dazu geführt, dass der Regierungsrat und der Grosse Rat des Kantons Basel-Stadt einer zweiten Erweiterung des Tech Parks Basel zugestimmt haben. Anfang 2018 wurde die Fläche um weitere 12 Biologie- und 2 Chemielabors, 34 Büros sowie weitere Gemeinschaftsräume (Sitzungszimmer, Küche, Aufenthaltsbereiche sowie Geräte- und Waschräume) erweitert.

Durch Auflösung des direkt benachbarten „Basel-Inkubator“ konnte dessen Flächen im Sommer 2019 ebenfalls in den Tech Park Basel integriert werden, so dass dieser nun gesamthaft rund 6700 m² Fläche umfasst.

FACTS & FIGURES

Juristische Einheit

Technologiepark Basel AG, gegründet am 31. März 2011

Eigentümer & Aktionär

Kanton Basel-Stadt

Verwaltungsrat

Samuel Hess (Präsident), Robert-Jan Bumbacher (Vizepräsident), Nina Ryser-Iten (Mitglied)

Geschäftsleitung und Team

Der Verwaltungsrat delegiert die Geschäftsleitung des Tech Parks Basel an Nina Ryser-Iten (Leitung Standortförderung im Amt für Wirtschaft und Arbeit). Weiter sind Christian Harr (Operativer Leiter), Brigitte Jäggi (Administration), Mitja Messerli (Marketing & Stakeholder Relations), Eveline Buso (Empfang) und Giovanni Attianese (Techn. Mitarbeiter & Stv. Empfang) für den Tech Park Basel tätig. Zudem bildet der Tech Park Basel seit Anfang 2020 einen Lernenden aus.

Eröffnung des Tech Parks Basel

Sommer 2011, 1. Erweiterung Sommer 2014, 2. Erweiterung Anfang 2018, Integration „Basel Inkubator“ Sommer 2019

Vermietungsstand per Juni 2022

>90%

Fläche

Seit Sommer 2014: ca. 3400 m²

Seit Anfang 2018: ca. 6400 m²

Seit Sommer 2019: ca. 6700 m²

Mietflächen

Büroflächen ab 12m²

Laborflächen ab 43m²

Mietpreise

Die Mietpreise im Tech Park Basel liegen auf Marktniveau. Der Tech Park Basel bietet innovativen Jungunternehmen aber zum Beispiel durch kurze Kündigungsfristen, der Verfügbarkeit von kleinen Mietflächen und der unentgeltlichen Vorhaltung von Expansionsflächen vorteilhafte Mietkonditionen.

Partner

Kanton Basel-Stadt, Swisscom

Kontakt

Technologiepark Basel AG

Hochbergerstrasse 60C

4057 Basel

Tel.: +41 61 633 22 00

www.techparkbasel.ch

Mieter im Tech Park

ABBA Therapeutics AG, www.abba-therapeutics.com



ABBA Therapeutics is a privately owned Swiss biotech company established in Basel in 2015. ABBA Therapeutics is committed to developing novel antibody drugs to modulate immune recognition and activation for anti-cancer therapy.

abel-systems, www.abel-systems.ch



abel-systems is a software engineering and IT consulting company specialized in custom web and mobile development. abel-systems develops and distributes the process- and document-management solution QM-Pilot. Furthermore we provide IT solutions for content management, web and mobile apps, as well as the development of individual solutions with modern technologies.

AlloCyte Pharmaceuticals AG, www.allocyte-pharmaceuticals.com



AlloCyte Pharmaceuticals AG is the privately held Swiss company translating its proprietary next-generation small molecule integrin pharmacology into therapies of transformative potential for immune-mediated diseases of high medical need.

Anaveon AG, <http://anaveon.com>



We are developing IL-2 complexes, which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.

ARTIDIS AG, www.artidis.com



Artidis AG focuses on development and commercialization of ARTIDIS (AUTOMATED AND RELIABLE TISSUE DIAGNOSTICS) nanotechnology platform for rapid diagnostics and treatment optimization. ARTIDIS is based on the atomic force microscope, which can determine the (nano)mechanical properties of native tissue by using a fine, nanometer-scale probe. able to examine tissue biopsies within an hour. By providing such nanomechanical profile of patient biopsy sample, ARTIDIS allows for rapid diagnosis of benign or malignant tumors and consequently optimization of treatment for cancer patients.

Aurealis Pharma AG, www.aurealispharma.com



AUREALIS PHARMA

Aurealis Pharma is a Swiss-Finnish biopharmaceutical company with a technology platform facilitating combination therapy embedded in one single product that can be administered in a safe, efficient and cost-effective way. Safe food-grade lactic acid bacteria release multiple therapeutic human proteins locally in diseased tissue. Our first products are immuno-therapeutics to treat patients with chronic inflammatory wounds and cancer indications.

BaseLaunch Accelerator, <https://baselaunch.ch/>



Building the next generation of biotech ventures. Providing space, help to secure funding, and experienced advisors who work closely with startups and entrepreneurs.

BioVersys AG, www.bioversys.com



BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics. We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC's (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.

BottMedical AG, <http://www.bottmedical.ch>



Bottmedical AG is a deep-tech spin-off from the University of Basel based on a IP portfolio related to the core polymer thin-film technology and more than 6 years' experience in nanotechnology of the founder team. Current commercialization projects relate to flexible micrometer-thin pressure sensor foils and soft electronic human machine Interfaces.

Cellestia Biotech S.A., www.cellestiabiotech.com



Cellestia Biotech S.A. is a privately-owned clinical stage biopharmaceutical company developing innovative first-in-class anti-cancer drugs originated from its unique discovery platform. Our clinical stage lead compound CB-103 is an oral small molecule protein-protein interaction inhibitor, acting as selective targeted therapy of NOTCH positive cancers.

Cimeio Therapeutics AG, <https://www.cimeio.com/>



Cimeio is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ for patients with debilitating and life-threatening diseases. Their proprietary technology platform is based on the discovery of novel protein variants, which when inserted into cells allow them to preserve function while resisting depletion by a precisely paired immunotherapy. This technology has significant therapeutic potential, which we are using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

Di Meliora AG, www.dimeliora.ch



Di Meliora AG is a spin-off of the University of Basel. Its BOTTICELLI implant system helps young dentists, who want to start placing dental implants by reducing complexity and increasing treatability. The company successfully raised funds early 2018 and is prototyping its first products. Through its patents it has also received a grant from the Swiss Federal Government for a CTI project to develop a ceramic implant.

Di Meliora AG

Edelweiss Connect GmbH, www.edelweissconnect.com



Edelweiss Connect manages collaborative projects to achieve goals in scientific research, infrastructure development or service provision. Edelweiss Connect acts both as the initiator of independent research projects (eg. in Discovery Informatics, Knowledge Management, Life Sciences, Drug Safety, Environmental Chemistry, Risk Assessment) and as a provider of integrated services for corporate clients in these areas.

FGen GmbH, www.fgen.ch



FGen is a service provider for biotechnology, life-sciences, and industry. The company was founded in 2011 by Prof. Sven Panke (Bioprocess Laboratory of the Department of Biosystems Science and Engineering of the ETH Zurich in Basel) and a number of his scientific fellows. FGen develops and performs high throughput experiments and assays on a contract basis for its customers from biotech, pharma, and chemical industries.

Dayagnostics AG,



dayagnostics AG is delivering solutions for accurate and fast pathogen detections in non-human applications such as food producing industry.

Intilaris LifeSciences GmbH, www.intilaris.com



Intilaris LifeSciences is a life science company focusing on productivity improvements and optimizations in Clinical development of pharmaceutical companies. The company provides GCP consulting and develops tools and systems that will lead to better utilization of the current resources and optimization of the clinical development processes. The customers of intilaris LifeSciences are the Clinical Development organizations of research oriented pharmaceutical companies. To a wider extend, intilaris LifeSciences serves the Clinical Development organizations of research oriented biotechnology companies as well.

KINARUS AG, www.kinarus.com



KINARUS AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.

Matterhorn Biosciences AG, matterhornbiosciences.com



Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins.

MOMM Diagnostics AG, <https://www.mommdiagnosics.com>



MOMM Diagnostics GmbH aims to develop a novel in-vitro diagnostic test for the early diagnosis of preeclampsia at the point-of-care. Preeclampsia affects 5-8% of all pregnancies and is one of the top five causes for maternal and infant illness and death. Early identification of the condition is crucial to minimize complications. PE screening, using a simple test for the definite diagnosis at the obstetrician's office helps to save lives and money.

NBE-Therapeutics GmbH, www.NBE-Therapeutics.com



NBE-Therapeutics is a new Swiss Life-Sciences company focused on the development of novel antibody-based therapeutics. NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates (ADCs), that can specifically target cancer cells for destruction.

Polyneuron Pharmaceuticals AG, <https://polyneuron.com>



Polyneuron is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases of the nervous system where a pathological role of anti-carbohydrate autoantibodies is well established. Polyneuron's platform focus is on rare but devastating autoimmune diseases of the nervous system with an unmet medical need.

Ridgeline Therapeutics AG, www.ridgelinetherapeutics.com



Ridgeline is Versant's newest discovery engine and has laboratories in Basel Technology Park. Ridgeline's leadership team hails from Roche and has a proven track record in drug development.

Skyhawk Therapeutics Europa GmbH,
<https://www.skyhawktx.com>



Skyhawk Therapeutics, with laboratories in Boston (U.S.) and the Basel Technology Park, is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression. Our founders are leading experts in developing small molecule therapeutics for RNA-based disease. Our first drug candidates are targeted towards cancers and neurological conditions, some of which were previously considered undruggable.

Stromal Therapeutics AG



Stromal Therapeutics develops new immunotherapeutic drugs for the treatment of cancer and chronic inflammatory diseases.

TargImmune Therapeutics AG, www.targimmune.com



TargImmune Therapeutics AG is a startup company established in March 2016 in Basel, Switzerland. TargImmune is developing a novel cancer-targeted platform technology CTPIC in the field of immuno-oncology and personalized therapy.

Vaximm AG, www.vaximm.com



VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

Versameb AG, <https://versameb.com>



Versameb is a Swiss based biotechnology platform company focusing on the optimized local delivery of therapeutic proteins, currently focusing on applications in regenerative medicine. Our vision is to both improve existing therapies as well as develop transformative therapies in entirely new applications in disease indications of high medial need. Versameb is funded by private international investors. We are committed to create substantial long-term value for our patients, shareholders and other stakeholders.